The business goals include achieving regional significance in the cardiometabolic and CNS therapeutic areas in the largest Central and Eastern European markets in the coming years taking advantage of the current range of products and the planned expansion of the product range in the existing and new therapeutic areas. In addition, the General Medicines Business Unit intends to serve the patients with OTC medications.
In recent years, Richter placed a lot of emphasis on the development of generic and fixed-dose combined products in the existing and new therapeutic areas, which enables the strengthening of the cardiometabolic and CNS areas, among which diabetes, multiple sclerosis and blood therapeutic fields stand out. In the last 3 years, we went through process and capability developments to make sure that Richter can serve patients with generic alternatives on the first day after the expiry of patent exclusivity.
Richter is committed to the development and supply of pharmaceuticals in a wide range of therapeutic areas, expanding to new geographies in order to improve access to affordable lifechanging treatments for patients worldwide.